Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome

Abstract excerpt

BACKGROUND AND OBJECTIVES: Atypical hemolytic uremic syndrome (aHUS) is associated with a congenital or acquired dysregulation of the complement alternative pathway that leads to continuous complement activation on host cells causing inflammation and damage. Eculizumab, a humanized mAb against complement protein C5, inhibits activation of the terminal complement pathway. DESIGN, SETTING, PARTICIPANTS, &...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood groups and transfusion
• Share to Complement system in diseases
• Share to Escherichia coli research studies